Cardiovascular Medicine

1 pages, 191 KB

Open AccessCommunication

Zum Hinschied von Prof. Dr. Martin E. Rothlin

by Ludwig K. von Segesser and Louis Egloff

Cardiovasc. Med. 2008, 11(4), 144; https://doi.org/10.4414/cvm.2008.01320 - 25 Apr 2008

Viewed by 47

Abstract

Am 10. Januar 2008 ist Martin Rothlin unerwartet in seinem 78 [...] Full article

2 pages, 423 KB

Open AccessInteresting Images

Coronary Fibromuscular Dysplasia: An Elusive Diagnosis

by Michel Oberson, Stavros Kosmidis, Felix Mahler, Mario Alerci, Rolf Wyttenbach, Paolo Tutta, Fabio Sartori and Augusto Gallino

Cardiovasc. Med. 2008, 11(4), 142; https://doi.org/10.4414/cvm.2008.01322 - 25 Apr 2008

Cited by 1 | Viewed by 43

Abstract

A 46-year-old woman with a history of typical chest pain at rest four weeks before admission, was referred by her general practitioner because of the presence of inverted T-waves (in V3–V5) [...] Full article

► Show Figures

Figure 1

2 pages, 471 KB

Open AccessInteresting Images

Anstrengungsinduzierte Synkopen

by Martin Vurma, Michael Klainguti and Martin Steiner

Cardiovasc. Med. 2008, 11(4), 140; https://doi.org/10.4414/cvm.2008.01325 - 25 Apr 2008

Cited by 1 | Viewed by 38

Abstract

Die notfallmässige Hospitalisation des 70jährigen Patienten erfolgte wegen rezidivierender Synkopen, welche jeweils unter leichter körperlicher Anstrengung aufgetreten waren [...] Full article

► Show Figures

Figure 1

9 pages, 700 KB

Open AccessEditorial

Der Perkutane Aortenklappenersatz

by Peter Wenaweser, Stephan Windecker, Ulrich Gerckens, Eberhard Grube and Bernhard Meier

Cardiovasc. Med. 2008, 11(4), 131; https://doi.org/10.4414/cvm.2008.01326 - 25 Apr 2008

Viewed by 47

Abstract

Percutaneous aortic valve replacement provides a new, alternative therapeutic option for high-risk or non-operable patients with severe symptomatic aortic valve stenosis. The two clinically used and commercially available devices are the Edwards-SAPIEN™ valve (bovine bioprosthesis) and the CoreValve Revalving™ system (porcine bioprosthesis). Clinical studies in selected patients revealed near normalisation of pressure gradients across the aortic valve with remarkable improvement of clinical symptoms. All cause mortality 30 days after the intervention amounted to approximately 12% and was lower than predicted for open valve surgery as estimated by established risk scores. Paravalvular leakage, coronary obstruction, highgrade AV node block, cerebrovascular events, and injury of the large vessels are potential complications of percutaneous aortic valve replacement. Meticulous screening of candidates is mandatory to evaluate the suitability for percutaneous aortic valve replacement and minimise the risk of peri-interventional complications. Operative valve replacement remains the gold standard for treatment of patients with severe, symptomatic aortic valve stenosis. Percutaneous aortic valve replacement may be considered in patients deemed inoperable due to severe comorbidities and very elderly patients. Full article

► Show Figures

Figure 1

7 pages, 248 KB

Open AccessReview

Die Medikamentöse Antiarrhythmische Therapie–Grundlagen

by Mehdi Namdar, Johannes Holzmeister and Corinna Brunckhorst

Cardiovasc. Med. 2008, 11(4), 124; https://doi.org/10.4414/cvm.2008.01323 - 25 Apr 2008

Viewed by 47

Abstract

The efficacy of antiarrhythmic drugs is based on the interaction of active substances with cellular ion channels, pumps, carriers and receptors. These control the cellular depolarisation and repolarisation and thus the propagation of physiological and pathological impulses. Not only a profound knowledge of their mode of action, but also the understanding of the most frequent rhythm disorders are essential for the meaningful use of antiarrhythmic drugs. This article gives an overview of the underlying mechanisms. Full article

► Show Figures

Figure 1

7 pages, 221 KB

Open AccessEditorial

Beta Blockers in Hypertension–To Use or Not to Use?

by Sripal Bangalore and Franz H. Messerli

Cardiovasc. Med. 2008, 11(4), 117; https://doi.org/10.4414/cvm.2008.01324 - 25 Apr 2008

Cited by 1 | Viewed by 59

Abstract

Traditionally, beta blockers were used as first line agents in the treatment of uncomplicated hypertension and recommended as a class by national and international guidelines despite paucity of evidence for their cardiovascular benefit. Evidence from recent trials and metaanalyses have questioned the use of beta blocker as the preferred agent. In this article we review the data available from clinical trials to argue that beta blockers are less efficacious compared to other antihypertensive agents currently available for patients with uncomplicated hypertension. The evidence suggests that beta blockers use in patients with uncomplicated hypertension is associated with little if any cardiovascular morbidity or mortality benefit when compared to other anti-hypertensive agents or even with placebo, whether in the elderly or in the young. In contrast to newer antihypertensives such as calcium antagonists and blockers of the renin angiotensin system, beta blockers have numerous adverse effects. Based on the evidence or lack there of, we argue that beta blockers should no longer be recommended for the treatment of uncomplicated hypertension. Full article

► Show Figures

Figure 1

Journal Menu

Journal Browser

Cardiovasc. Med., Volume 11, Issue 4 (04 2008) – 6 articles

Further Information

Guidelines

MDPI Initiatives

Follow MDPI